Table 1.

FDA-approved HPV vaccines

	Gardasil	Cervarix
Proper name	HPV quadrivalent (types 6, 11, 16, 18) vaccine, recombinant	HPV bivalent (types 16 and 18) vaccine, recombinant
Manufacturer	Merck & Co.	GlaxoSmithKline Biologicals
VLP types	6, 11, 16, 18	16, 18
Adjuvant	225 µg aluminum hydroxyphosphate sulfate	500 µg aluminum hydroxide, 50 µg3-O-deacylated-4′-monophosphoryl lipid A
Schedule	0, 2, 6 mo	0, 1, 6 mo
Indications	Vaccination in females between 9 and 26 y of age for prevention of diseases caused by HPV 6/11/16/18: Cervical cancer Genital warts Cervical adenocarcinoma in situ (AIS) Cervical intraepithelial neoplasia (CIN) grades 1, 2, and 3 Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 Prevention of vulvar and vaginal cancer Vaccination in boys and men between 9 and 26 y of age for the prevention of genital warts caused by HPV 6/11 Vaccination in people aged 9 to 26 y for the prevention of anal cancer and associated precancerous lesions caused by HPV 6/11/16/18	Vaccination in females between 9 and 25 y of age for the prevention of disease caused by HPV 16/18: Cervical cancer CIN grades 1, 2, and 3 AIS

Data from FDA-approved indications for Gardasil. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM094042. Accessed December 10, 2012; and FDA-approved indications for Cervarix. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM094042. Accessed December 10, 2012.